GlassScriptPhysician profile
Matthew A Levine
NPI 1245327170
$7,080.10
in general payments reported to CMS, 2019-2025
41 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $593 · 2021: $917 · 2022: $1,170 · 2023: $1,378 · 2024: $1,333 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,629.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,628.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,512.38 | 2019-2025 | |
| Boston Scientific Corporation | $876.48 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $628.84 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $530.41 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $524.79 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $433.98 | 2019-2025 | Camzyos, Eliquis |
| Philips North America LLC | $300.06 | 2020-2025 | Coronary Other, Extended Holter |
| Abbott Laboratories | $238.98 | 2020-2025 | Amplatzer Amulet, Amplatzer Talisman, Supera |
| Pfizer INC. | $206.76 | 2019-2025 | |
| Novo Nordisk INC | $183.66 | 2021-2025 | Wegovy, Ozempic |
| Actelion Pharmaceuticals US, INC. | $178.94 | 2019-2023 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $159.15 | 2019-2024 | Farxiga, Brilinta |
| Amgen INC. | $135.21 | 2019-2025 | Repatha, Repatha |
| Chiesi USA, INC. | $116.67 | 2020-2021 | |
| Heartflow, INC. | $114.27 | 2023 | Ffrct |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.